FI76553C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara aminosulfonylalkylnitrosoureaderivat. - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara aminosulfonylalkylnitrosoureaderivat. Download PDFInfo
- Publication number
- FI76553C FI76553C FI833266A FI833266A FI76553C FI 76553 C FI76553 C FI 76553C FI 833266 A FI833266 A FI 833266A FI 833266 A FI833266 A FI 833266A FI 76553 C FI76553 C FI 76553C
- Authority
- FI
- Finland
- Prior art keywords
- chloroethyl
- nitrosourea
- ethyl
- formula
- process according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 28
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 16
- 239000001257 hydrogen Substances 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 15
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 10
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 6
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 4
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 58
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 40
- -1 dipropylaminosulfonyl Chemical group 0.000 claims description 33
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 239000004157 Nitrosyl chloride Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- VPCDQGACGWYTMC-UHFFFAOYSA-N nitrosyl chloride Chemical compound ClN=O VPCDQGACGWYTMC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019392 nitrosyl chloride Nutrition 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 claims description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 4
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 claims description 3
- PRKAYYDFYSQRMQ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(2-hydroxyethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound OCCNS(=O)(=O)CCNC(=O)N(N=O)CCCl PRKAYYDFYSQRMQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- CVMVXHUAVILQEG-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitroso-3-(2-piperidin-1-ylsulfonylethyl)urea Chemical compound ClCCN(N=O)C(=O)NCCS(=O)(=O)N1CCCCC1 CVMVXHUAVILQEG-UHFFFAOYSA-N 0.000 claims description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical group [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 238000007034 nitrosation reaction Methods 0.000 claims description 2
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 150000003672 ureas Chemical class 0.000 claims description 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims 2
- ARNQWXVAHAYACL-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(2-methoxyethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound COCCNS(=O)(=O)CCNC(=O)N(N=O)CCCl ARNQWXVAHAYACL-UHFFFAOYSA-N 0.000 claims 1
- NURVUPJHOGEIGJ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-3-methyl-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCN(C)C(=O)N(N=O)CCCl NURVUPJHOGEIGJ-UHFFFAOYSA-N 0.000 claims 1
- VBYJDSHYVNCROJ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-[ethyl(propyl)sulfamoyl]ethyl]-1-nitrosourea Chemical compound CCCN(CC)S(=O)(=O)CCNC(=O)N(N=O)CCCl VBYJDSHYVNCROJ-UHFFFAOYSA-N 0.000 claims 1
- HKVADYRNINSBQC-UHFFFAOYSA-O 2-chloroethyl-[2-[2-hydroxyethyl(methyl)sulfamoyl]ethylcarbamoylamino]-oxoazanium Chemical compound CN(CCO)S(=O)(=O)CCNC(=O)N[N+](=O)CCCl HKVADYRNINSBQC-UHFFFAOYSA-O 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 239000004202 carbamide Substances 0.000 abstract description 4
- 150000004008 N-nitroso compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 231100001274 therapeutic index Toxicity 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100021906 Cyclin-O Human genes 0.000 description 4
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- LZDSILRDTDCIQT-UHFFFAOYSA-N dinitrogen trioxide Chemical compound [O-][N+](=O)N=O LZDSILRDTDCIQT-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- PIZGQSWCZNVPFH-UHFFFAOYSA-N 2-amino-n,n-dimethylethanesulfonamide;hydrochloride Chemical compound Cl.CN(C)S(=O)(=O)CCN PIZGQSWCZNVPFH-UHFFFAOYSA-N 0.000 description 3
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229960003440 semustine Drugs 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical compound NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 description 2
- RUIGAHCLEIQCRC-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]urea Chemical compound CN(C)S(=O)(=O)CCNC(=O)NCCCl RUIGAHCLEIQCRC-UHFFFAOYSA-N 0.000 description 2
- DGUVEYAZTOUCEJ-UHFFFAOYSA-N 2-aminoethanesulfonamide;hydron;chloride Chemical compound Cl.NCCS(N)(=O)=O DGUVEYAZTOUCEJ-UHFFFAOYSA-N 0.000 description 2
- RXQNKKRGJJRMKD-UHFFFAOYSA-N 5-bromo-2-methylaniline Chemical compound CC1=CC=C(Br)C=C1N RXQNKKRGJJRMKD-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FUSGACRLAFQQRL-UHFFFAOYSA-N N-Ethyl-N-nitrosourea Chemical compound CCN(N=O)C(N)=O FUSGACRLAFQQRL-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000005979 thermal decomposition reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- KZZILGDAMASFTG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) n-(2-chloroethyl)-n-nitrosocarbamate Chemical compound ClCCN(N=O)C(=O)ON1C(=O)CCC1=O KZZILGDAMASFTG-UHFFFAOYSA-N 0.000 description 1
- DAJARBUJEJVGDQ-UHFFFAOYSA-N (4-nitrophenyl) n-(2-chloroethyl)-n-nitrosocarbamate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)N(CCCl)N=O)C=C1 DAJARBUJEJVGDQ-UHFFFAOYSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- SYLKSJRDGLRPIU-UHFFFAOYSA-N 1,1-bis[2-(dimethylsulfamoyl)ethyl]-3-nitrosourea Chemical compound CN(C)S(=O)(=O)CCN(C(=O)NN=O)CCS(=O)(=O)N(C)C SYLKSJRDGLRPIU-UHFFFAOYSA-N 0.000 description 1
- KWTKHWMAWPEISV-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(cyclopropylmethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCN(C(=O)N(CCCl)N=O)CC1CC1 KWTKHWMAWPEISV-UHFFFAOYSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- ACLWRDBCKGMURO-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)propyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)C(C)CNC(=O)N(CCCl)N=O ACLWRDBCKGMURO-UHFFFAOYSA-N 0.000 description 1
- UZGRTWBSSSBFBV-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dipropylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CCCN(CCC)S(=O)(=O)CCNC(=O)N(CCCl)N=O UZGRTWBSSSBFBV-UHFFFAOYSA-N 0.000 description 1
- SATDQZURIZSSKI-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(methylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CNS(=O)(=O)CCNC(=O)N(N=O)CCCl SATDQZURIZSSKI-UHFFFAOYSA-N 0.000 description 1
- ISRFYMURZYDPFN-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-[(1-hydroxy-2-methylpropan-2-yl)sulfamoyl]ethyl]-1-nitrosourea Chemical compound OCC(C)(C)NS(=O)(=O)CCNC(=O)N(N=O)CCCl ISRFYMURZYDPFN-UHFFFAOYSA-N 0.000 description 1
- YNODPWNZUSTNGC-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-[methoxy(methyl)sulfamoyl]ethyl]-1-nitrosourea Chemical compound CON(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl YNODPWNZUSTNGC-UHFFFAOYSA-N 0.000 description 1
- IBIDCWMPCUHQCJ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[3-(dimethylsulfamoyl)propyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCCNC(=O)N(N=O)CCCl IBIDCWMPCUHQCJ-UHFFFAOYSA-N 0.000 description 1
- XRRCROCEBQBJHF-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[4-(dimethylsulfamoyl)butyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCCCNC(=O)N(N=O)CCCl XRRCROCEBQBJHF-UHFFFAOYSA-N 0.000 description 1
- DXVCAMZHQNJBSQ-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[5-(dimethylsulfamoyl)pentyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCCCCNC(=O)N(N=O)CCCl DXVCAMZHQNJBSQ-UHFFFAOYSA-N 0.000 description 1
- VQVHVJMFEBRIPO-UHFFFAOYSA-N 1-(2-chloroethyl)-3-diazo-1-nitrosourea Chemical compound ClCCN(N=O)C(=O)N=[N+]=[N-] VQVHVJMFEBRIPO-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CPIZYYSABVGCPR-UHFFFAOYSA-N 3-[2-(dimethylsulfamoyl)ethyl]-1-methyl-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(C)N=O CPIZYYSABVGCPR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- DYSWELCOTYGVEX-UHFFFAOYSA-N ClCCN(C(=O)N(C(C)S(=O)(=O)N(C)C)C1CCCCC1)N=O Chemical compound ClCCN(C(=O)N(C(C)S(=O)(=O)N(C)C)C1CCCCC1)N=O DYSWELCOTYGVEX-UHFFFAOYSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910004064 NOBF4 Inorganic materials 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KEJOCWOXCDWNID-UHFFFAOYSA-N Nitrilooxonium Chemical compound [O+]#N KEJOCWOXCDWNID-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000011952 anionic catalyst Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- IDNHOWMYUQKKTI-UHFFFAOYSA-M lithium nitrite Chemical compound [Li+].[O-]N=O IDNHOWMYUQKKTI-UHFFFAOYSA-M 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Optical Head (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Gyroscopes (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8205324A SE8205324L (sv) | 1982-09-17 | 1982-09-17 | Nya n-nitrosoforeningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder |
| SE8205324 | 1982-09-17 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI833266A0 FI833266A0 (fi) | 1983-09-13 |
| FI833266A7 FI833266A7 (fi) | 1984-03-18 |
| FI76553B FI76553B (fi) | 1988-07-29 |
| FI76553C true FI76553C (fi) | 1988-11-10 |
Family
ID=20347890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI833266A FI76553C (fi) | 1982-09-17 | 1983-09-13 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara aminosulfonylalkylnitrosoureaderivat. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4613695A (https=) |
| EP (1) | EP0106123B1 (https=) |
| JP (1) | JPS5973562A (https=) |
| KR (1) | KR910006763B1 (https=) |
| AT (1) | ATE17235T1 (https=) |
| AU (1) | AU559738B2 (https=) |
| CA (1) | CA1242200A (https=) |
| DE (1) | DE3361719D1 (https=) |
| DK (1) | DK423983A (https=) |
| ES (1) | ES525662A0 (https=) |
| FI (1) | FI76553C (https=) |
| GR (1) | GR79656B (https=) |
| HK (1) | HK35389A (https=) |
| HU (1) | HU194817B (https=) |
| IE (1) | IE55901B1 (https=) |
| IL (1) | IL69660A0 (https=) |
| NO (1) | NO159084C (https=) |
| NZ (1) | NZ205534A (https=) |
| PH (1) | PH21576A (https=) |
| PT (1) | PT77349B (https=) |
| SE (1) | SE8205324L (https=) |
| SG (1) | SG789G (https=) |
| ZA (1) | ZA836569B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001158A (en) * | 1984-04-11 | 1991-03-19 | Centre National De La Recherche Scientifique | Nitrosoureas compounds preparation thereof and utilization thereof in anticancerous |
| WO2001098268A2 (en) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Piperidine amides as modulators of chemokine receptor activity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE50228B1 (en) * | 1979-10-03 | 1986-03-05 | Kefalas As | Nitrosourea derivatives,process for preparing them,and pharmaceutical compositions containing them |
-
1982
- 1982-09-17 SE SE8205324A patent/SE8205324L/xx not_active Application Discontinuation
-
1983
- 1983-08-26 IE IE2006/83A patent/IE55901B1/en not_active IP Right Cessation
- 1983-09-05 AU AU18707/83A patent/AU559738B2/en not_active Ceased
- 1983-09-05 IL IL69660A patent/IL69660A0/xx not_active IP Right Cessation
- 1983-09-05 ZA ZA836569A patent/ZA836569B/xx unknown
- 1983-09-06 US US06/529,718 patent/US4613695A/en not_active Expired - Fee Related
- 1983-09-08 KR KR1019830004238A patent/KR910006763B1/ko not_active Expired
- 1983-09-08 DE DE8383108853T patent/DE3361719D1/de not_active Expired
- 1983-09-08 AT AT83108853T patent/ATE17235T1/de not_active IP Right Cessation
- 1983-09-08 EP EP83108853A patent/EP0106123B1/en not_active Expired
- 1983-09-09 NZ NZ205534A patent/NZ205534A/en unknown
- 1983-09-13 FI FI833266A patent/FI76553C/fi not_active IP Right Cessation
- 1983-09-15 PH PH29543A patent/PH21576A/en unknown
- 1983-09-15 GR GR72451A patent/GR79656B/el unknown
- 1983-09-16 DK DK423983A patent/DK423983A/da not_active Application Discontinuation
- 1983-09-16 NO NO833354A patent/NO159084C/no unknown
- 1983-09-16 HU HU833220A patent/HU194817B/hu not_active IP Right Cessation
- 1983-09-16 ES ES525662A patent/ES525662A0/es active Granted
- 1983-09-16 CA CA000436928A patent/CA1242200A/en not_active Expired
- 1983-09-16 PT PT77349A patent/PT77349B/pt not_active IP Right Cessation
- 1983-09-16 JP JP58171054A patent/JPS5973562A/ja active Granted
-
1989
- 1989-01-05 SG SG7/89A patent/SG789G/en unknown
- 1989-04-27 HK HK353/89A patent/HK35389A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9493409B2 (en) | Process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine | |
| ES2431618T3 (es) | Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-N-metil-1-naftamida y productos intermedios sintéticos de la misma | |
| ES2959967T3 (es) | Procedimiento de preparación deN-(5-(4-(4-formil-3-fenil-1h-pirazol-1-il)pirimidin-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida | |
| JP2025505892A5 (https=) | ||
| KR860007201A (ko) | 항생 작용을 갖는 악타가르딘의 염기성 모노카르복시아미드 유도체의 제조방법 | |
| FI76553B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara aminosulfonylalkylnitrosoureaderivat. | |
| KR101100064B1 (ko) | 나프록센의 니트로옥시유도체 제조방법 | |
| KR20040072665A (ko) | [1,4,5]-옥사디아제핀 유도체의 제조방법 | |
| Uchida et al. | The thermal decomposition of N, O-diacyl-Nt-butylhydroxylamines. III. Novel routes to 2-substituted 1, 2-benzisothiazol-3-(2H)-ones. | |
| JP5270549B2 (ja) | Ｈｉ−６ジメタンスルホネートの製造方法 | |
| US4803223A (en) | Substituted aminophenyl urea derivatives | |
| US3138636A (en) | Anthranilic acid derivatives | |
| KR20010005943A (ko) | 0-(3-아미노-2-히드록시-프로필)-히드록심산할라이드의 제조방법 | |
| US4221803A (en) | Substituted dibenzyl ethers and pharmaceutical compositions containing said ethers for the treatment of infections | |
| JP2678758B2 (ja) | 新規なプロパン誘導体 | |
| KR102815514B1 (ko) | 엑토인계 화합물 및 이의 제조방법 | |
| KR870000203B1 (ko) | 9-카바모일플루오렌 유도체의 제조방법 | |
| Lown et al. | Synthesis of 3 (2-haloethyl) aryltriazenes and study of their reactions in aqueous solution | |
| KR101142283B1 (ko) | 2-아미노티아졸 카르복사미드 유도체의 신규한 제조방법 | |
| CA1293263C (en) | Process for the preparation of substituted sulfonamidobenzamides and a novel intermediate thereto | |
| CA1102803A (en) | Process for the production of substituted sulphoximides | |
| Haske et al. | Preparation of unsymmetrical dithiooxamides | |
| Chen et al. | The Synthesis of Novel Derivatives of 1, 5-Dihydro-4-Mercapto-2, 6-Dioxo-1, 3, 5, 2-Triazaphosphorine and Their Antitumor Activity | |
| JPH0528708B2 (https=) | ||
| US20020120142A1 (en) | Method for making 8-hydroxyjulolidine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: AKTIEBOLAGET LEO |